|
CA3087192A1
|
|
Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
|
|
US2012142627A1
|
|
Monophosphate prodrugs of dapd and analogs thereof
|
|
WO2011041512A2
|
|
Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases
|
|
US2012135951A1
|
|
3′-azido purine nucleotide prodrugs for treatment of viral infections
|
|
US2010130381A1
|
|
HIV-1 reverse transcriptase codon deletion and its use in the management and treatment of HIV infections
|
|
WO9609764A1
|
|
Method, compositions, and apparatus for treating and preventing respiratory viral infections
|
|
US5750493A
|
|
Method to improve the biological and antiviral activity of protease inhibitors
|
|
AU3725293A
|
|
Sensitizing agents for use in boron neutron capture therapy
|
|
CA2055463A1
|
|
Antiviral therapy using thiazine and xanthene dyes
|
|
IE893023L
|
|
Polyoxometallate compounds as antiviral agents
|
